Quick Cases: Key Concepts in the Contemporary Management of HIV

This collection of case-based expert commentaries reinforces core concepts relevant to the contemporary management of HIV. Various experts provide practical perspectives on recent treatment advances and everyday clinical challenges.

Eric S. Daar, MD Charles B. Hicks, MD Lisa Hightow-Weidman, MD, MPH Daniel R. Kuritzkes, MD Paul E. Sax, MD Kathleen E. Squires, MD David A. Wohl, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 10, 2017 Expired: No longer available for credit

Here is my take on how emerging investigational agents may address unmet needs in HIV treatment.

Paul E. Sax, MD Released: April 10, 2017

Here is my take on current data with dual-therapy regimens and when they might be considered.

Paul E. Sax, MD Released: April 11, 2017

Will long-acting cabotegravir plus rilpivirine injections satisfy patient desire for less frequent dosing? Here is my take.

Paul E. Sax, MD Released: April 12, 2017

In an older patient managing hypertension, reactive airways disease, and moderate renal insufficiency, what ART regimen would you recommend?

David A. Wohl, MD Released: May 31, 2017

Which statins should be avoided in patients receiving boosted ART regimens?

David A. Wohl, MD Released: June 1, 2017

What qualifies an HIV-infected past or current smoker for annual lung cancer screening using low-dose CT scans?

David A. Wohl, MD Released: May 31, 2017

In some cases, gaining trust may be the most important aspect of a patient’s care.

Lisa Hightow-Weidman, MD, MPH Released: May 12, 2017

Understanding a patient’s life circumstances may be as important as any other aspect of providing good care.

Lisa Hightow-Weidman, MD, MPH Released: May 12, 2017

One-tablet regimens may not always be the best choice of ART, but the best choice is always the one the patient is willing to take.

Lisa Hightow-Weidman, MD, MPH Released: May 12, 2017

What key factors influence the choice of ART in older women?

Kathleen E. Squires, MD Released: April 10, 2017

Which ARV classes best avoid DDIs with hormonal contraception?

Kathleen E. Squires, MD Released: April 10, 2017

Which regimen may work best during the third trimester?

Kathleen E. Squires, MD Released: April 20, 2017

For a newly diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?

Eric S. Daar, MD Released: June 21, 2017

Would you switch a virologically suppressed patient who is experiencing PI toxicity to a PI-sparing regimen if they had a history of nonadherence and resistance?

Eric S. Daar, MD Released: June 21, 2017

What is the optimal ART regimen for a patient with CKD and CVD who desires an STR?

Eric S. Daar, MD Released: June 21, 2017

Is switching TDF to TAF justified in osteopenic women?

Charles B. Hicks, MD Released: April 21, 2017

Is the switch to a 2-drug regimen in virologically suppressed HIV-infected patients feasible?

Charles B. Hicks, MD Released: April 20, 2017

How do phase III data on doravirine affect the potential for future therapy with NNRTIs?

Charles B. Hicks, MD Released: April 21, 2017

How do phase III data on bictegravir and doravirine affect the potential future HIV treatment landscape? Here’s my take.

Daniel R. Kuritzkes, MD Released: September 11, 2017

Can switching ART improve cardiovascular or bone health?

Daniel R. Kuritzkes, MD Released: September 11, 2017

Should dual-therapy ART be considered in the first-line setting for some patients?

Daniel R. Kuritzkes, MD Released: September 12, 2017